SCHEMBL2632761

SCHEMBL2632761

CCC(N)C(C)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5928059 1.00
SCHEMBL2632763 1.00
Hydrochloric Acid SCHEMBL30904950 0.97
SCHEMBL10641706 0.78 SLC7A5 (0.43)
Acetic Acid SCHEMBL432875 0.77 SLC1A3 (0.56)
SCHEMBL8299449 0.77
SCHEMBL14886193 0.77
SCHEMBL6367974 0.77
SCHEMBL12271123 0.77
Acetic Acid SCHEMBL432873 0.77 SLC1A3 (0.56)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0729468-A1 NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 1996-09-04 EP claimed
EP-0729468-A4 NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS LILLY CO ELI (US) 1996-07-12 EP claimed
US-20240207425-A1 AURISTATIN LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2024-06-27 US disclosed
WO-2023205786-A1 DIDEHYDRO-3'-DEOXY-4'-ETHYNYLTHYMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS ROME THERAPEUTICS, INC. (US) 2023-10-26 WO disclosed
US-20230322743-A1 NOVEL SAFRYLAMINE DERIVATIVES HAVING PRODRUG PROPERTIES MIHKAL GMBH (CH) 2023-10-12 US disclosed
US-9796705-B2 Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases MERCK SHARP & DOHME CORP. (US) 2017-10-24 US disclosed
US-20170137429-A1 ANTI-INFLUENZA COMPOSITIONS AND METHODS BIOCRYST PHARMACEUTICALS, INC. 2017-05-18 US disclosed
US-20170008879-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. (US) 2017-01-12 US disclosed
US-9526794-B2 Injectable dendrimer hydrogel nanoparticles WAYNE STATE UNIVERSITY (US) 2016-12-27 US disclosed
US-9499554-B2 Anti-influenza compositions and methods BIOCRYST PHARMACEUTICALS, INC. (US) 2016-11-22 US disclosed
US-20160297823-A1 SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME INSTITUTE FOR DRUG DISCOVERY, LLC 2016-10-13 US disclosed
US-7326707-B2 Bicyclic melanocortin-specific compounds PALATIN TECHNOLOGIES INCORPORATED (US) 2008-02-05 US disclosed
US-7326707-B2 Bicyclic melanocortin-specific compounds PALATIN TECHNOLOGIES INCORPORATED (US) 2008-02-05 US disclosed
US-20070173636-A1 Method for preparing polyfunctionalized peptides and/or proteins via native chemical ligation NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-07-26 US disclosed
US-20070161589-A1 Antisense Modulation of CD40 Expression ISIS PHARMACEUTICALS, INC. (US) 2007-07-12 US disclosed
US-20070155670-A1 Pyrrolidine Melanocortin-Specific Compounds PALATIN TECHNOLOGIES, INC. (US) 2007-07-05 US disclosed
US-20070155670-A1 Pyrrolidine Melanocortin-Specific Compounds PALATIN TECHNOLOGIES, INC. (US) 2007-07-05 US disclosed
US-7189755-B2 Pyrrolidine melanocortin-specific compounds PALATIN TECHNOLOGIES, INC. (US) 2007-03-13 US disclosed
US-7189755-B2 Pyrrolidine melanocortin-specific compounds PALATIN TECHNOLOGIES, INC. (US) 2007-03-13 US disclosed
US-7157430-B2 (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases IDUN PHARMACEUTICALS, INC. (US) 2007-01-02 US disclosed